Applicability of the Notthingham Prognostic Index for predicting the survival of triple-negative invasive breast cancer in a single Italian center

Objective: Triple-negative breast cancer (TNBC) is recognized to have a very poor prognosis due to its strong tendency to develop distant metastases. The present study aims to evaluate the applicability of the Nottingham Pronostic Index (NPI) in women affected or not by invasive TNBC in our centre. Materials and Methods: A retrospective study on women operated in the authors’ Department for invasive breast cancer between January 2002 and January 2007 was carried out, with a follow up of at least five years. Patients were divided into three groups based on the three prognostic categories of NPI and every category was again subdivided in TNBC or non-TNBC. Data was collected about tumor histology and biological assessment, patients characteristics, treatment, and follow up in terms of overall survival (OS). Results: The authors included 917 women operated for invasive breast cancer during this period, at a mean age of 61.4 ± 12.58 years. TNBC prevalence was 8% (71/917). Among the NPI classes, they found respectively a five-and eight-years’ OS of 99% (98-100%) and 97% (95-98%) in group 1, 88% (83-93%) and 83% (77-89%) in group 2, and 69% (59-80%) and 55% (44-70%) in group 3 (p < 0.05). After stratification of every NPI group between TNBC and non-TNBC, they found a five-years’ OS in TNBC and non-TNBC strata of respectively 94% (87-100%) and 99% (98-100%) in group 1 (p<0.05), 85% (71-100%) and 89% (84-94%) in group 2 (p0.834), and 47% (26-85%) and 73% (63-85%) in group 3 (p < 0.05). Conclusions: NPI resulted as a very simple and valuable prognostic tool and TNBC, when associated with NPI groups, significantly modified the prognostic value of NPI itself.

Margins; Resection margins; Surgical margins; Breast cancer; Breast conserving surgery; Recurrence

[1] Bertozzi S., Londero A.P., Giacomuzzi F., Angione V., Carbone A., Petri R., et al.: “Applicability of two different validated models to predict axillary non-sentinel lymph node status by sentinel node biopsy in a single Italian center”. Breast Cancer, 2015, 22, 350.

[2] Bernardi S., Bertozzi S., Londero A.P., Gentile G., Angione V., Petri R.: “Influence of surgical margins on the outcome of breast cancer patients: a retrospective analysis”. world J. Surg., 2014, 38, 2279.

[3] Cedolini C., Bertozzi S., Seriau L., Londero A.P., Concina S., Moretti E., et al.: “Feasibility of concervative breast surgery and intraoperative radiation therapy for early breast cancer: a single-center, open, non-randomized, prospective pilot study”. Oncol. Rep., 2014, 31, 1539.

[4] Bernardi S., Bertozzi S., Londero A.P., Giacomuzzi F., Angione V., Dri C., et al.: “Nine years of experience with the sentinel lymph node biopsy in a single Italian center: a retrospective analysis of 1,050 cases”. world J. Surg., 2012, 36, 714.

[5] Kollias J., Murphy C.A., Elston C.W., Ellis I.O., Robertson J.F., Blamey R.W.: “The prognosis of small primary breast cancers”. Eur. J. Cancer, 1999, 35, 908.

[6] Galea M.H., Blamey R.W., Elston C.E., Ellis I.O.: “The Nottingham Prognostic Index in primary breast cancer”. Breast Cancer Res. Treat., 1992, 22, 207.

[7] Fulford L.G., Reis-Filho J.S., Ryder K., Jones C., Gillett C.E., Hanby A., et al.: “Basal-like grade III invasive ductal carcinoma of the breast: patterns of metastasis and long-term survival”. Breast Cancer Res., 2007, 9, R4.

[8] Dent R., Hanna W.M., Trudeau M., Rawlinson E., Sun P., Narod S.A.: “Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status”. Cancer, 2009, 115, 4917.

[9] Hicks D.G., Yoder B.J., Short S., Tarr S., Prescott N., Crowe J.P., et al.: “Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patients”. Clin. Cancer Res., 2006, 12, 6702.

[10] Arnone P., Zurrida S., Viale G., Dellapasqua S., Montagna E., Arnaboldi P., et al.: “The TNM classification of breast cancer: need for change”. Updates Surg., 2010, 62, 75.

[11] Cedolini C., Bertozzi S., Londero A.P., Bernardi S., Seriau L., Concina S., et al.: “Type of breast cancer diagnosis, screening, and survival”. Clin. Breast Cancer, 2014, 14, 235.

[12] Cedolini C., Bertozzi S., Seriau L., Londero A.P., Concina S., Cattin F., et al.: “Eight-year experience with the intraoperative frozen section examination of sentinel lymph node biopsy for breast cancer in a North-Italian university center”. Int. J. Clin. Exp. Pathol., 2014, 7, 364.

[13] Bertozzi S., Londero A.P., Petri R., Bernardi S.: “Isolated axillary nodal swelling and cancer of unknown primary”. Eur. J. Gynaecol. Oncol., 2015, 36, 131.

[14] Bernardi S., Bertozzi S., Londero A.P., Gentile G., Giacomuzzi F., Carbone A.: “Incidence and risk factors of the intraoperative localization failure of nonpalpable breast lesions by radio-guided occult lesion localization: a retrospective analysis of 579 cases”. world J. Surg., 2012, 36, 1915.

[15] Bernardi S., Bertozzi S., Londero A.P., Angione V., Petri R., Giacomuzzi F.: “Prevalence and risk factors of intraoperative identification failure of sentinel lymph nodes in patients affected by breast cancer”. Nucl. Med. Commun., 2013, 34, 664.

[16] Driul L., Bernardi S., Bertozzi S., Schiavon M., Londero A.P., Petri R.: “New surgical trends in breast cancer treatment: conservative interventions and oncoplastic breast surgery”. Minerva Ginecol., 2013, 65, 289.

[17] Reis-Filho J.S., Lakhani S.R.: “Breast cancer special types: why bother?” J. Pathol., 2008, 216, 394.

[18] Reis-Filho J.S., Westbury C., Pierga J.Y.: “The impact of expression profiling on prognostic and predictive testing in breast cancer”. J. Clin. Pathol., 2006, 59, 225.

[19] Brenton J.D., Carey L.A., Ahmed A.A., Caldas C.: “Molecular classification and molecular forecasting of breast cancer: ready for clinical application?” J. Clin. Oncol., 2005, 23, 7350.

[20] Badve S., Dabbs D.J., Schnitt S.J., Baehner F.L., Decker T., Eusebi V., et al.: “Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists”. Mod. Pathol., 2011, 24, 157.

[21] Albergaria A., Ricardo S., Milanezi F., Carneiro V., Amendoeira I., Vieira D., et al.: “Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?” BMC Cancer, 2011, 11, 299.

[22] Megha T., Neri A., Malagnino V., Caruso S., Onorati M., Roviello F., et al.: “Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estrogen receptor signaling remain the best predictors of relapse and survival in a series of 289 cases”. Cancer Biol. Ther., 2010, 9, 266.

[23] Rakha E.A., El-Sayed M.E., Green A.R., Lee A.H.S., Robertson J.F., Ellis I.O.: “Prognostic markers in triple-negative breast cancer”. Cancer, 2007, 109, 25.

[24] Rakha E.A., Soria D., Green A.R., Lemetre C., Powe D.G., Nolan C.C., et al.: “Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer”. Br. J. Cancer, 2014, 110, 1688.

[25] Kurshumliu F., Gashi-Luci L., Kadare S., Alimehmeti M., Gozalan U.: “Classification of patients with breast cancer according to Nottingham prognostic index highlights significant differences in immunohistochemical marker expression”. world J. Surg. Oncol., 2014, 12, 243.